Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)

Author: Brand K.

Source: Current Gene Therapy, Volume 2, Number 2, May 2002 , pp. 255-271(19)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

OR

Price: $63.10 plus tax (Refund Policy)

Abstract:

Matrix metalloproteinases (MMPs) are of crucial importance for the invasive behavior of primary tumors and their metastases. MMP activity is regulated by the four naturally occurring tissue inhibitors of metalloproteinases (TIMPs). It has been shown that overexpression of TIMPs in tumors of various origins leads to reduced tumor growth and formation of metastases. More recently, antitumor efficacy by in vivo gene transfer of TIMPs has been reported in several clinically relevant animal models. This review analyses the therapeutic potential of the TIMPs from a cancer gene therapeutic point of view with particular emphasis on cell culture and in vivo data.

Keywords: Cancer Gene Therapy; Metalloproteinases; Angiogenesis; Tissue Inhibitors

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1566523024605564

Publication date: 2002-05-01

Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page